Potential treatment for rare autoimmune disorder adapted from CAR-T therapy in study
Evidence from a small-scale clinical trial suggests that a variation of the blood cancer immunotherapy chimeric antigen receptor T-cell (CAR-T) could be adapted to treat myasthenia gravis (MG), an autoimmune disorder of the nervous system. Read More
Eli Lilly acquiring immune therapy developer Dice Therapeutics for $2.4B
Eli Lilly said this week it has inked an agreement to acquire Dice Therapeutics, a biopharma firm developing novel oral therapeutic candidates, for $2.4 billion in cash. Read More
Conferences
Science Briefs
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
